Sign in

You're signed outSign in or to get full access.

Andrew Paine

Andrew Paine

Senior Analyst at CLSA

Sydney, NSW, AU

Andrew Paine is a Senior Analyst at CLSA specializing in healthcare and biotechnology equity research, with coverage of prominent Australian companies including Ramsay Health Care, Sonic Healthcare Limited, Pro Medicus Limited, and Immutep. He has issued 14 ratings with a 56% profitable recommendation rate and an average return per transaction of 4.10%, reflecting a solid performance track record on platforms like TipRanks. Paine began covering equities at CLSA in the early 2020s and has distinguished himself through insightful research and well-calibrated price targets, such as an Outperform rating for Immutep in May 2025. He holds relevant industry credentials for equity research and maintains active sector alignment with healthcare and biotech innovations.

Andrew Paine's questions to Telix Pharmaceuticals (TLX) leadership

Question · H2 2025

Andrew Paine asked about the clarity and durability of Telix's competitive moat in the maturing PSMA market, especially with potential new competition, and how advancements in camera technology support the sensitivity of PSMA imaging.

Answer

Christian Behrenbruch, CEO and Managing Director of Telix Pharmaceuticals, reiterated that competitive barriers are multiple, encompassing product, clinical, manufacturing, and supply chain aspects. He also highlighted a significant step change in PET camera sensitivity over the last 3-5 years, enabling earlier disease detection and complementing tracer development, citing PSA levels down to fractions of a nanogram per mil in recent China studies.

Ask follow-up questions

Fintool

Fintool can predict Telix Pharmaceuticals logo TLX's earnings beat/miss a week before the call

Question · H2 2025

Andrew Paine asked about the competitive moat in the PSMA market given potential competition, and how changes in camera technology support the sensitivity of PSMA imaging.

Answer

CEO Christian Behrenbruch highlighted multiple competitive barriers including product, clinical, manufacturing, and supply chain. He noted a significant step change in PET camera sensitivity over the last three to five years, leading to earlier disease detection and supporting tracer development, as demonstrated in recent China studies detecting very low PSA levels.

Ask follow-up questions

Fintool

Fintool can write a report on Telix Pharmaceuticals logo TLX's next earnings in your company's style and formatting

Andrew Paine's questions to RESMED (RMD) leadership

Question · Q1 2025

Andrew Paine asked for commentary on the competitive landscape in the EU, specifically if ResMed is seeing a declining presence from a key competitor, which could enable market share gains.

Answer

CEO Michael Farrell stated the competitive environment is what it "always was" and attributed strong European performance to improved internal execution, a cohesive commercial team, and superior logistics, rather than a specific competitor's decline. He reiterated that the primary goal is expanding the patient funnel.

Ask follow-up questions

Fintool

Fintool can predict RESMED logo RMD's earnings beat/miss a week before the call